氢溴酸西酞普兰鼻用温敏凝胶的处方优化及体外性质评价

丛志新, 李爽, 黄晶, 吴春芝, 谷福根

中国药学杂志 ›› 2020, Vol. 55 ›› Issue (5) : 375-382.

PDF(5948 KB)
PDF(5948 KB)
中国药学杂志 ›› 2020, Vol. 55 ›› Issue (5) : 375-382. DOI: 10.11669/cpj.2020.05.008
论著

氢溴酸西酞普兰鼻用温敏凝胶的处方优化及体外性质评价

  • 丛志新1,2, 李爽1,2, 黄晶1,2, 吴春芝2, 谷福根2*
作者信息 +

Formulation Optimization of Citalopram Hydrobromide Thermosensitive Nasal Gel and Its In Vitro Properties

  • CONG Zhi-xin1,2, LI Shuang1,2, HUANG Jing1,2, WU Chun-zhi2, GU Fu-gen2*
Author information +
文章历史 +

摘要

目的 优化氢溴酸西酞普兰(citalopram hydrobromide,CTH)鼻用温敏凝胶的处方并对其体外性质进行评价。方法 以泊洛沙姆407(F127)和卡波姆940(CP940)作为凝胶基质材料,胶凝温度与胶凝时间为观察指标,采用星点设计-效应面法和单因素实验法优化凝胶基质处方;同时,以离体羊鼻黏膜为模型,采用Franz透皮扩散池法筛选药物透皮吸收促渗剂,最后采用冷法制备CTH鼻用温敏凝胶并进行体外性质评价;采用无膜溶出法测定制剂的体外溶蚀率及体外释放率;采用透析膜法测定其体外释放度。同时,考察温度及pH对该制剂黏度的影响。结果 CTH鼻用温敏凝胶最优处方组成为:CTH 8.0%、F127 20.27%、CP940 0.17%、DM-β-CD 3.0%、尼泊金乙酯0.05% 及适量水。该制剂的胶凝温度为32.5 ℃,胶凝时间为42 s,pH值为5.0,55 min时体外累积溶蚀率与药物累积释放率均大于90%,且二者具有良好线性相关性(r2=0.998 6);该制剂在8 h内体外累积释药为92%,其释药过程符合Higuchi动力学方程。温度及pH对该制剂的黏度均有不同程度的影响。结论 采用星点设计-效应面法和单因素法优化处方所制备CTH鼻用温敏凝胶其胶凝温度、胶凝时间及pH值适宜,符合鼻用制剂要求,其体外释药具明显缓释特征。

Abstract

OBJECTIVE To optimize the formulation of citalopram hydrobromide (CTH ) thermosensitive nasal gel and further evaluate its in vitro properties. METHODS With gelling temperature and gelling time as evaluating indexes, central composite design-response surface and single factor experimental design method were used to optimize the formulation of CTH thermosensitive nasal gel by using poloxamer 407(F127) and carbomer 940 (CP940) as gel materials. Meanwhile, nasal mucosa permeation enhancer for CTH was then sieved by using Franz diffusion cell and ex vivo sheep nasal mucosa as experimental model. Finally, CTH thermosensitive nasal gel was prepared with cold method and then its in vitro properties was evaluated. In vitro cumulative erosion and cumulative release rate of the drug thermosensitive nasal gel were investigated by membrane-free dissolution method and dialysis membrane method, respectively. Moreover, the effect of temperature and pH on the viscosity of the drug nasal gel formulation was also evaluated. RESULTS The optimal formulation of the thermosensitive nasal gel consisted of CTH 8.0%, F127 20.27%, CP940 0.17%, DM-β-CD 3.0%, ethylparaben 0.05% and distilled water. The gelling temperature, gelling time and pH of the drug thermosensitive nasal gel were found to be about 32.5 ℃,42 s and 5.0, respectively. The in vitro cumulative erosion and cumulative release percentage were both greater than 90% in 55 min and furthermore there was good linear correlation between these two parameters (r=0.998 6). Additionally, in vitro cumulative release of the drug from the gel formulation was determined to be 92% within 8 h, which conformed to Higuchi kinetic equation. Furthermore, the viscosity of the drug nasal gel was influenced by temperature as well as pH in different extent. CONCLUSION The optimized formulation of the CTH thermosensitive nasal gel with central composite design-response surface method and single factor design method shows suitable gelling temperature, gelling time, pH value for nasal preparation and obvious in vitro drug sustained release characteristics.

关键词

氢溴酸西酞普兰 / 泊洛沙姆407 / 卡波姆940 / 鼻用温敏凝胶 / 处方优化 / 星点设计-响应面法 / 体外溶蚀 / 体外释放度

Key words

citalopram hydrobromide / poloxamer 407 / carbomer 940 / thermosensitive nasal gel / formulation optimization / central composite design-response surface / in vitro erosion / in vitro release

引用本文

导出引用
丛志新, 李爽, 黄晶, 吴春芝, 谷福根. 氢溴酸西酞普兰鼻用温敏凝胶的处方优化及体外性质评价[J]. 中国药学杂志, 2020, 55(5): 375-382 https://doi.org/10.11669/cpj.2020.05.008
CONG Zhi-xin, LI Shuang, HUANG Jing, WU Chun-zhi, GU Fu-gen. Formulation Optimization of Citalopram Hydrobromide Thermosensitive Nasal Gel and Its In Vitro Properties[J]. Chinese Pharmaceutical Journal, 2020, 55(5): 375-382 https://doi.org/10.11669/cpj.2020.05.008
中图分类号: R944   

参考文献

[1] XU M Y,WANG Y,ZHAO Y, et al. Effect of Ganmai Dazao Decoction on BDNF and SERT gene expression in prefrontal lobe and amygdala and on serum level of 5-HT in rats with depression [J]. Shanghai J Tradit Chin Med(上海中医药杂志),2019,53(3):89-92.
[2] LI Y,HE M,ZHANG L Y,et al. Advances in the neuroanatomy and pathophysiology of depression [J]. Anhui Med Pharm J(安徽医药),2017,21(10):1751-1759.
[3] BEZCHLIBNYK-BUTLER K, ALEKSIC I, KENNEDY S H. Citalopram-a review of pharmacological and clinical effects[J]. J Psychiatry Neurosci,2000,25(3):241-254.
[4] ZHAO L, CAO M H. Clinical effect of citalopram hydrobromide in the treatment of medium term Parkinson′s disease patients with depression[J]. Chin Comm Doc(中国社区医师), 2016, 32(34):98.
[5] HUANG C T, TSAI M J, LIN Y H, et al. Effect of microemulsions on transdermal delivery of citalopram:optimization studies using mixture design and response surface methodology[J]. Int J Nanomed, 2013, 8(1):2295-2304.
[6] PARDESHI C V, BELGAMWAR V S. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier:an excellent platform for brain targeting[J]. Expert Opin Drug Del, 2013, 10(7):957-972.
[7] MARZOUK M A,OSMAN D A,ABD EL-FATTAH A I. Formulation and in vitro evaluation of a thermoreversible mucoadhesive nasal gel of itopride hydrochloride[J]. Drug Dev Ind Pharm,2018,44(11):1857-1867.
[8] HE Y Z.Characteristics of carbomer and its applications in pharmaceutics[J].Chin J Clin Rational Drug Use(临床合理用药杂志),2019,12(15):180-181.
[9] BALAKRISHNAN P, PARK E K, SONG C K, et al. Carbopol-incorporated thermoreversible gel for intranasal drug delivery[J]. Molecules, 2015, 20(3):4124-4135.
[10] HUANG Q Y, XIONG L, WANG H M, et al. Optimization for preparation technology of Cangai volatile oil dextrin inclusion compound/ in situ nasal thermosensitive gel by central composite design-response surface method[J]. Chin J Inf Tradit Chin Med (中国中医药信息杂志),2016,23(11):86-89.
[11] LI X L,YE Y L,PENG J, et al. Study on preparation of compound metronidazole gel[J]. J Chin Prescr Drug (中国处方药),2018,16(6):29-30.
[12] XIANG B P. Study on a HPLC method for analysis of citalopram hydrobromide [J]. Sichuan Chem Ind (四川化工), 2007,10 (6):30-31,37.
[13] HAO W Q, LIN Y, YUAN X, et al. Preparation of salviae miltiorrhiza and ligustrazine hydrochloride nasal thermosensitive in situ gel and study on characterization of its nasal mucosal permeability [J]. J Chin Med Mat(中药材),2016,39(7):1605-1609.
[14] ZHANG C Y,ZHAO Y C,FAN Y F. Preparation and in vitro release of norfloxacin thermosensitive in situ gel for vaginal use[J]. Chin Pharm(中国药师), 2017, 20(11):1983-1986.
[15] MA J B,QU Q,DONG K,et al. Study on in vitro dissolution and drug release for ibuprofen in situ gel [J]. Northwest Pharm J (西北药学杂志),2013,28(5):513-514.
[16] YIN Y Z,CHEN L,XIE X L, et al. Preparation and in vitro evaluation of mesalazine thermosensitive in situ gel for rectum [J]. Chin J New Drugs(中国新药杂志),2019,28(12):1484-1489.
[17] FATHALLA Z, VANGALA A, LONGMAN M, et al. Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: design, characterisation, toxicity and transcorneal permeation studies[J]. Eur J Pharm Biopharm, 2017, 114:119-134.
[18] MURA P, MENNINI N, NATIVI C, et al. In situ mucoadhesive-thermosensitive liposomal gel as a novel vehicle for nasal extended delivery of opiorphin[J]. Eur J Pharm Biopharm, 2018, 122:54-61.
[19] KULKARNI J A, AVACHAT A M. Pharmacodynamic and pharmacokinetic investigation of cyclodextrin-mediated asenapine maleate in situ nasal gel for improved bioavailability [J]. Drug Dev Ind Pharm, 2017, 43(2):234-245.
[20] SHERJE A P, LONDHE V. Development and evaluation of pH-responsive cyclodextrin-based in situ gel of paliperidone for intranasal delivery[J]. AAPS Pharm Sci Tech, 2018, 19(1):384-394.
[21] FAN H M,CONG Z X,GU F G. Preparation and in vitro properties of thermosensitive in situ nasal gel of donepezil hydrochloride[J]. Cent South Pharm(中南药学), 2018,16(9):1194-1199.
[22] YE X C, OU J L, HONG B X, et al. Preparation and characteristics of itraconazole vaginal thermosensitive in situ gels [J]. Cent South Pharm(中南药学),2014,12(6):551-556.
[23] HU X, HU R F, BAI Z W. Optimization and evaluation of a pH-sensitive in situ gel of nystatin for vaginal delivery system [J]. Chin J New Drugs(中国新药杂志),2013,22(15):1812-1818.
PDF(5948 KB)

Accesses

Citation

Detail

段落导航
相关文章

/